



Human serum albumin promotes self-renewal and expansion of umbilical cord blood CD34⁺ hematopoietic stem/progenitor cells

Jing Hua^{1#}, Tingting Jiao^{2#}, Yongna Qiao³, Shuo Zhang⁴, Taiwu Xiao¹, Yan Zhang⁵, Jinqiang Yan⁶

¹Department of Hematology, Liaocheng People's Hospital and Clinical School of Shandong First Medical University, Liaocheng, China;

²Reproductive Medical Center, Department of Obstetrics and Gynecology, Chinese PLA General Hospital, the Seventh Medical Center of PLA General Hospital, Beijing, China; ³Department of Clinical Laboratory, Dongchangfu People's Hospital, Dongchangfu Branch of Liaocheng People's Hospital and Clinical School of Shandong First Medical University, Liaocheng, China; ⁴State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China; ⁵Department of Gynecology and Obstetrics, Liaocheng People's Hospital and Clinical School of Shandong First Medical University, Liaocheng, China; ⁶Department of Pathology, Liaocheng People's Hospital and Clinical School of Shandong First Medical University, Liaocheng, China

Contributions: (I) Conception and design: J Hua, S Zhang, J Yan, Y Zhang; (II) Administrative support: None; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: J Hua, S Zhang, Y Qiao, T Xiao, J Yan, Y Zhang; (V) Data analysis and interpretation: J Hua, S Zhang, Y Qiao, T Xiao, J Yan, Y Zhang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

***These authors contributed equally to this work.**

Correspondence to: Yan Zhang. Department of Gynecology and Obstetrics, Liaocheng People's Hospital and Clinical School of Shandong First Medical University, Liaocheng, China. Email: zhangyan850907@126.com; Jinqiang Yan. Department of Pathology, Liaocheng People's Hospital and Clinical School of Shandong First Medical University, Liaocheng, China. Email: yanjinqiang1988@163.com.

Background: We investigated the effect of human serum albumin (HSA) on human umbilical cord blood (UCB) CD34⁺ hematopoietic stem/progenitor cells (HSPCs) cultured *in vitro* and transplanted *in vivo*.

Methods: Human umbilical cord blood mononuclear cells were obtained by density gradient centrifugation. CD34⁺ cells were then sorted by CD34 conjugated magnetic microbeads. The sorted cells were cultured with or without HSA for 8 days *in vitro*. After 8 days, all cells were harvested for flow phenotyping and colony formation cell (CFC) experiments. The cells were injected into immunodeficient mice (NOD/Shi-scid/IL2Rγnull, NOG) via intravenous injections. From 4 weeks post-transplantation, flow cytometry was used to calculate human cell chimerism in the peripheral blood (PB) every 2 weeks. Flow phenotyping of human cell chimerism in bone marrow and spleen was calculated 16 weeks post-transplantation.

Results: Compared to the control group, CD34⁺ cells cultured with HSA increased significantly *in vitro*. The long-term engraftment of HSPCs and the hematopoietic multilineage reconstruction capacity were preserved by HSA. Normal engraftment of human cells could be maintained via HSA treatment could maintain normal engraftment of human cells in recipient PB.

Conclusions: Here, we found that HSA was beneficial to maintaining CD34⁺ cell expansion and short-term colony formation *in vitro* and optimizing multilineage reconstitution in immunodeficient mice *in vivo*.

Keywords: Hematopoietic stem/progenitor cells (HSPCs); human serum albumin (HSA); expansion *in vitro*; transplantation

Submitted Nov 15, 2022. **Accepted for publication** Jan 06, 2023. **Published online** Jan 13, 2023.

doi: 10.21037/atm-22-6383

View this article at: <https://dx.doi.org/10.21037/atm-22-6383>

View this article at: <https://dx.doi.org/10.21037/atm-22-6383>

Introduction

Hematopoietic stem/progenitor cells (HSPCs) play an important role in the hematopoietic system by maintaining adult hematopoiesis through self-renewal capability and multipotent differentiation. Self-renewal capability is the ability of HSPCs to give rise to themselves without differentiation, while multipotent differentiation is the ability to differentiate into all blood cell types. In 1988, Spangrud's group determined the surface marker phenotype of mouse hematopoietic stem cells as Thy-1^{low}Lin⁻Sca-1⁺. In lethally irradiated mice, hematopoietic stem cells were the main population with functional long-term hematopoietic reconstitution capability (1). Rapid engraftment of HSPCs in syngeneic and allogeneic hosts was also possible at radioprotective doses (2).

In the human adult hematopoietic system, the turnover of blood cells is estimated to be more than 1 million per second (3). Because mature blood cells are predominantly short lived, HSPCs are required to continuously provide more differentiated blood cells (4).

HSPCs represent only 0.5–5% of mononuclear cells in human fetal liver, umbilical cord blood, and adult bone marrow (5,6). CD34 is the first surface marker used to enrich human HSPCs. In addition, populations with different levels of CD38 expression play different roles in CD34⁺ HSPCs. Although the majority of CD34⁺ cells express CD38, mainly CD38^{-/low}CD90⁺ HSPCs induce differentiation into phenotypic and functional multilineage blood cells, including lymphoid and myeloid cells (7,8).

HSPC transplantation is an effective therapeutic strategy for a variety of malignant and nonmalignant diseases, including hematological malignancies such as acute myeloid leukemia and acute lymphoblastic leukemia (8–11).

Since HSPCs are increasingly being used, some obstacles have emerged, including limited sources of HSPCs and insufficient doses in clinical treatment. Human umbilical cord blood (UCB) provides a valuable source of HSPC acquisition and is superior to bone marrow (BM) and peripheral blood (PB) mobilization. Several studies have aimed to increase the yield of HSPCs derived from UCB by improving *in vitro* expansion to overcome the insufficient progenitor cells in adult HSPC transplants (12,13). HSPCs derived from UCB and PB can also be used for culturing in serum-free medium *in vitro* (14). Red blood cells (RBCs) or platelets generated from UCB-HSPCs *in vitro* have been shown to have potential for clinical applications (15,16). Although preclinical experiments showed that the *in vitro* expansion of HSPCs is feasible and safe for transplantation (17), transplantation treatment remains limited by HSPC expansion *in vitro*. Therefore, it is necessary to enhance cultivation strategies to improve the yield and quality of HSPCs *in vitro*. Recently, studies have demonstrated that StemRegenin 1 (SR1), a purine derivative obtained by high-throughput screening, can support the *in vitro* expansion ability of CD34⁺ cells in the presence of cytokines (18,19). In addition, screened pyrimidine indole derivatives were further modified to obtain UM171, which also supported the expansion of hematopoietic progenitor cells (20,21).

Human serum albumin (HSA) is a group of plasma proteins produced by the human liver. HSA consists of a polypeptide chain that binds to a variety of hydrophobic ligands and maintains blood osmotic pressure. As an important protein in human plasma, HSA accounts for about 50–60% of plasma protein content. Clinical trials have shown that expanded HSPCs can enhance the therapeutic effect significantly after being washed, concentrated, and resuspended in a solution containing HSA for transplantation and injection (22). However, there is no research on the effect of HSA in HSPC culture *in vitro*. Therefore, we added a small dose of HSA into serum-free medium to explore the effect of HSA in HSPC expansion *in vitro* and engraftment *in vivo*. We present the following article in accordance with the ARRIVE reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6383/rc>).

Methods

Animals

The immunodeficient mice used in the experiments were

Highlight box

Key findings

- Human serum albumin has an effect on human umbilical cord blood CD34⁺ hematopoietic stem/progenitor cells.

What is known and what is new?

- Human serum albumin maintains CD34⁺ cell expansion and short-term colony formation *in vitro*.
- Human serum albumin optimizes multilineage reconstitution in immunodeficient mice *in vivo*.

What is the implication, and what should change now?

- Human serum albumin plays an important role in efficient hematopoietic stem/progenitor cell transplantation strategy.

Table 1 Antibodies used in flow cytometric analysis

Antibody	Clone	Catalog#	Vender
CD34-APC/Cy7	561	343614	BioLegend
CD49f-PE	eBioGoH3	12-0495-82	eBioscience
CD90-FITC	5E10	328108	BioLegend
CD38-PE/Cy7	HB7	328108	Invitrogen
hCD45-APC	2D1	17-9459-42	Invitrogen
hCD45-FITC	2D1	11-9459-42	Invitrogen
mCD45-PE/Cy7	30-F11	25-0451-82	Invitrogen
mCD45-APC	30-F11	17-0451-82	Invitrogen
CD19-FITC	HIB19	11-0199-42	Invitrogen
CD33-PE	HIM3-4	12-0339-42	Invitrogen
CD3-Percp/cy5.5	HIT3	300328	BioLegend
CD56-APC	CMSSB	17-0567-42	Invitrogen
CD41-PE/Cy7	HIP8	303716	BioLegend
CD235a-PE	HIR2	12-9987-82	Invitrogen

female NOD/Shi-scid/IL2R γ null (NOG) mice (7–8 weeks). A total of 20 mice were obtained for use in this study. Sixteen mice were included, and 4 mice were excluded because of instrumentation or technical failure during animal preparation. All experimental mice were randomized into different groups. The mice were purchased from Vital River Laboratory Animal Technology (Beijing, China) and housed in specific-pathogen-free (SPF) conditions, with free access to food and water. All animal protocols were approved by the Animal Care and Use Committee of Liaocheng People's Hospital (No. 370726220100172283), in compliance with institutional guidelines for the care and use of animals.

Human UCB-CD34⁺ cell isolation

We collected samples from consenting donors at the gynecology and obstetrics department of Liaocheng People's Hospital. Mononuclear cells (MNC) from umbilical cord blood were isolated by density gradient centrifugation using Ficoll-Lympholyte separation (Cedarlane, Burlington, Canada). After labeling of CD34⁺ cells by MACS CD34 MicroBeads (Miltenyi Biotec, Auburn, CA, USA), CD34 microbead-labeled cells were isolated using an LS column. We performed as the manufacturer's protocol to operate

QuadroMACS separator (Miltenyi Biotec). The purity of the isolated CD34⁺ cells was about 86.37% \pm 3.56% (n=6). This study was approved by the Ethics Committee of Liaocheng People's Hospital and Clinical School of Shandong First Medical University (No. 2012004), and was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from all participants included in this study.

UCB-CD34⁺ cell *in vitro* culture

For phenotypic and functional assays, CD34⁺ cells were cultured in *in vitro* expansion medium. A protocol was prepared before the study without registration. Iscove's Modified Dulbecco's Medium (IMDM; Life Technologies, Carlsbad, CA, USA) supplemented with 1% penicillin/streptomycin/glutamine (P/S/G, Life Technologies), 1% insulin-transferrin-selenium-ethanolamine (ITSX, Life Technologies), 10 mM HEPES (Life Technologies), 10 ng/mL stem cell factor (SCF; PeproTech, East Windsor, NJ, USA), and 100 ng/mL TPO (PeproTech), with or without 0.1% HSA (Albumin Bioscience, Huntsville, AL, USA) was used as an *in vitro* expansion medium for CD34⁺ cells. The absolute number of input cells was calculated based on purity and flow cytometry data of isolated CD34⁺ cells. CD34⁺ cells were resuspended in *in vitro* expansion medium and seeded at 1 \times 10⁴/well into 96-well plates (Corning Life Sciences, Tewksbury, MA, USA). The medium was changed every 4 days. UCB-CD34⁺ cells were cultured at 37 °C in 5% CO₂ for 8 days.

Flow cytometric analysis

Cells cultured *in vitro* were dissociated to form a single-cell suspension and washed with fluorescence-activated single cell sorting (FACS) buffer [1% fetal bovine serum (FBS) and 1 mM ethylenediaminetetraacetic acid (EDTA) in phosphate-buffered saline (PBS)] 3 times. Cells obtained from PB, BM, and spleen (SP) *in vivo* were dissociated to form a single-cell suspension as above. The cells were stained at 4 °C for 30–60 minutes in FACS buffer supplemented with a combination of the antibodies and fluorophores listed in *Table 1*. The stained cells were then analyzed using an Aria II (BD Biosciences, Franklin Lakes, NJ, USA) flow cytometer. The relative percentages and absolute numbers of different cell subsets were determined by flow cytometry. Data analysis was performed using

FlowJo 10 software (Tree Star, Inc., San Carlos, CA, USA).

Colony forming cell assay (CFC)

On day 8 of *in vitro* culture, cells were harvested and resuspended in IMDM. Indicated numbers of cells were transferred to 1 mL of MethoCult H4034 Optimum (STEMCELL Technologies, Vancouver, Canada). The mixture was then transferred to ultra-low attachment 24-well plates (Corning). Cells were cultured at 37 °C in 5% CO₂ with 100% humidity for 14 days. The plates were then visually scored for colony-forming unit-granulocyte/macrophage (CFU-GM), colony-forming unit-erythrocyte (CFU-E), burst-forming unit-erythroid (BFU-E), colony-forming unit granulocyte (CFU-G), colony-forming unit-macrophage (CFU-M), and colony-forming unit granulocyte/erythrocyte/macrophage/megakaryocyte (CFU-GEMM).

Transplantation and monitoring of human HSCs in NOG mice

Mice (7–8 weeks) were irradiated at a dose of 2 Gy for 4 hours before transplantation. Cells cultured *in vitro* were harvested and washed 3 times with PBS. They were then resuspended in 50 µL of PBS and injected into the tail vein via intravenous injections. The PB of mice was obtained at 4, 6, 8, 10, 12, 14, and 16 weeks post-transplantation for flow cytometry. At 16 weeks, BP and SP cells were obtained after transplantation for human cell chimera analysis.

Statistical analysis

All data are presented as the mean ± standard deviation (SD). We used the GraphPad Prism software version 7.0 (GraphPad Software, Inc., La Jolla, CA, USA) to do statistical analyses. Statistical differences were evaluated using two-tailed Student's *t*-test, with significance at *P* values <0.05.

Results

MACS-isolated human UCB-CD34⁺ cells (1×10⁴ cells/well) from were seeded into 96-well plates for *in vitro* culture for 8 days. The cells were cultured in expansion medium supplemented with or without HSA, respectively. Cells were cultured at 37 °C in 5% CO₂ for 8 days. The mixture of expanded cells was then obtained and analyzed by flow

cytometry. These cells were injected, respectively, into sublethal irradiated severe combined immunodeficient NOG mice via the tail vein. Human cell chimera analysis in PB at 4, 6, 8, 10, 12, 14, and 16 weeks were measured by flow cytometry. Human cell engraftment in BM and SP 16 weeks post-transplantation were also measured by flow cytometry (Figure 1A).

HSA enhanced expansion of CD34⁺HSPCs in vitro

CD34 is a clinical biomarker for hematopoietic stem cell transplant (HSCT). CD34⁺ cells are the main source of long-term regenerative potential donor tissue in HSCT (23). As a surface marker, CD34 protein typically diminishes and disappears as cells mature. Thus, we compared the percentage of cells expressing CD34 in live cells among uncultured UCB-MNC, isolated UCB-CD34⁺ cells, and cultured cells (treated with or without HSA). As shown in Figure 1B, UCB-CD34⁺ cells account for only about 1–2% of UCB-MNC. We enriched UCB-CD34⁺ cells by MACS for further culture *in vitro* (Figure 1B). When in a serum-free culture system (IMDM + 1% ITSX + 1% P/S/G + 10 mM HEPES + 10 ng/mL hSCF + 100 ng/mL hTPO, supplemented with or without HSA) for 8 days, HSA treatment significantly increased CD34⁺ cells in both percentage and cell number, leading to a twofold increase in the number of CD34⁺ cells and up to 1.3-fold in percentage (Figure 1B–1D).

HSA sustained short-term colony formation of CD34⁺HSPC in vitro culture

Based on recent evidence, we also selected CD38, CD49f, and CD90 as common cell surface markers for identifying human HSPCs (24,25). Representative flow cytometry profiles of phenotype-defined subpopulations can be seen in Figure 2A. HSA treatment obviously increased the percentage of CD34⁺CD38⁻ cells compared with the control group, while there was no significant difference in certain subpopulations' proportions (CD49f, CD90) of CD34⁺ cells (Figure 2A and Figure S1A). In addition, we assessed the short-term colony formation capacity of cultured UCB-CD34⁺ cells with or without HSA treatment by CFC assay. Cultured UCB-CD34⁺ cells were planted in flat-bottomed 24-well plates in MethoCult H4434 Optimum for 14 days. We scored CFU-GM, CFU-E, BFU-E, CFU-M, and CFU-GEMM visually after 14 days in culture. HSA-treated cells showed a prominent colony-forming potential of BFU-E.




Figure 1 HSA enhanced expansion of CD34⁺HSPCs *in vitro*. (A) Schematic diagram of UCB-derived CD34⁺ cell *in vitro* culture and xenograft experiment *in vivo*. (B) Representative flow cytometry profiles of phenotypically defined subpopulations with or without 8 days *in vitro* culture. The percentage of CD34 was detected in uncultured UCB-MNC and UCB-CD34⁺ cells, and also in cultured UCB-CD34⁺ cells treated with or without HSA. (C) The percentage of CD34⁺ cells treated with or without HSA for 8 days *in vitro* culture was statistically analyzed (n=7). All data represent the means ± SD by two-tailed unpaired Student's *t*-test, *, P<0.05. (D) The number of CD34⁺ cells treated with or without HSA for 8 days *in vitro* culture was statistically analyzed (n=7). All data represent the means ± SD by two-tailed unpaired Student's *t*-test, **, P<0.01. UCB, umbilical cord blood; BM, bone marrow; SP, spleen; CFC, Colony forming cell; NOG, NOD/Shi-scid/IL2Rγnull; HSA, human serum albumin.




Figure 2 HSA sustained short-term colony formation of CD34⁺HSPCs *in vitro* culture. (A) Representative flow cytometry profiles of phenotypically defined subpopulations with or without 8 days *in vitro* culture. The proportion of CD38, CD49f, and CD90 in CD34⁺ cell populations were detected in uncultured UCB-MNC and uncultured UCB-CD34⁺ cells, and also in cultured UCB-CD34⁺ cells treated with or without HSA. (B) Colonies derived from HSA-treated cells following an additional 14 days in MethoCult H4034 Optimum culture (n=7). All data represent the means ± SD by two-tailed unpaired Student's *t*-test, **, P<0.01, *, P<0.05. CFC, Colony forming cell; BFU-E, burst-forming unit-erythroid; CFU-GM, colony-forming unit-granulocyte/macrophage; HSA, human serum albumin; UCB, umbilical cord blood.

A comparable increase with HSA treatment was observed in GM colonies compared to the control group (Figure 2B and Figure S1B). Representative morphological images of BFU-E colonies are shown in Figure S1C. Cultured cells with HSA treatment showed higher potential for short-term colony formation.

HSA promoted CD34⁺HSPC engraftment in NOG Mice

Although CFC assays are commonly used to assess the multilineage differentiation potential of HSPCs, xenotransplantation into immunodeficient mice is considered the gold standard for assessing the ability of cultured HSPCs to engraft and reconstitute all blood cell lineages (26). The proportion of human CD45⁺ (hCD45⁺) cells in PB of mice gradually increased from week 4 to week 16 post-transplantation. Although human cell engraftment in PB of recipient NOG mice showed no significant difference between 2 groups from week 4 to week 10 post-transplantation, some mice in the HSA group generated a slightly higher level of engraftment at 12 and 14 weeks (Figure 3A). At week 16, the proportion of hCD45⁺ cells in PB of the mice in the HSA group was higher than that in the control group, demonstrating that HSA-treated cells generated hCD45⁺ cells more than twofold compared to controls (Figure 3A,3B). These results showed that normal engraftment of human cells could be maintained via HSA treatment in recipient PB.

We also detected human cell chimerism in the BM and SP at week 16 post-transplantation. According to the percentage of hCD45⁺ cells in BM, we regarded a baseline that the level of hCD45⁺ cells not less than 2% in BM of mice recipients for successful engraftment. These recipients, such as the control group (5 out of 8) and HSA group (2 out of 8) did not achieve positive engraftment (percentage of hCD45⁺ cells less than 2%). These suggested a slight facilitation in engraftment of human cells after culturing with HSA *in vitro* (Figure 3C). In addition, there was no significant difference in engraftment in SP between the 2 groups of recipient NOG mice (Figure 3D). Consistent with the results, we showed the flow phenotype of hCD45⁺ cells analyzed in PB, BM, and SP at week 16 post-transplantation (Figure 3E).

HSA maintained multilineage reconstitution capacity in NOG mice

Assessment of multilineage hematopoietic reconstitution

in BM and SP at week 16 post-transplantation was subsequently conducted. We observed that post-transplantation, HSA-treated cells could differentiate into multilineages, including lymphoid and myeloid cells, without significant difference compared to uncultured cells. Therefore, we detected lymphoid cells such as B-lymphoid cells (hCD45⁺CD19⁺), T-lymphoid cells (hCD45⁺CD3⁺), natural killer cells (NK cells, hCD45⁺CD56⁺). We also detected myeloid cells (hCD45⁺CD33⁺), megakaryocytes (hCD45⁺CD41a⁺), and erythroid cells (hCD45⁺CD235a⁺) by flow cytometry. Accordingly, this implied an unaffected multilineage reconstitution of human cells after culturing with HSA *in vitro* (Figure 4 and Figure S2).

Taken together, these results *in vivo* suggested that HSA might have slightly promoted the engraftment of cultured UCB-CD34⁺ cells post-transplantation and retained multilineage potential during culture *in vitro*.

Discussion

Recently, a number of different approaches have been demonstrated for enhancing efficient expansion of HSPCs. Studies have shown that expansion efficiency can be improved by stromal cocultures, such as autologous umbilical vein endothelial cells (HUVECs) (27), human stromal placenta layer (28), and human mesenchymal stem cells (MSCs) (29). In addition, coating matrix can improve the *in vitro* expansion efficiency of HSPCs such as collagen I matrix (30) and fibronectin (31,32). Further, molecules for expanding HSPCs have gradually been tapped, including the bioactive peptide SL-13R (33), the activator of Wnt signaling 6-bromoindirubin-3'-oxime (BIO) (34), and Levistilide A (35). It is also feasible to replace FBS with HSA during the process of washing and resuspending HSPCs (22). HSA has multiple functions in *in vitro* culture. HSA might be used as a “molecular carrier” or provide an amino acid source for HSPCs. In this study, we demonstrated that HSA improved HSPC *in vitro* expansion. Compared to FBS, HSA as a prescription drug has played an important role in clinical application without immunological rejection. However, HSA with unclear composition has limited study of its mechanism.

Improving the expansion of UCB-derived CD34⁺ HSPCs *in vitro* is necessary to meet the demand for clinical transplants and also improve the transplantation reconstruction effect in clinical treatment. There are many methods for improving the expansion and engraftment of HSPCs, including cytokine combinations, small-molecule




Figure 3 HSA promoted CD34⁺HSPCs engraftment in NOG mice. (A) Human cell chimerism in PB of NOG mice was detected at 4, 6, 8, 10, 12, 14, and 16 weeks post-transplantation (n=8). All data represent the means \pm SD by two-tailed unpaired Student's *t*-test. **P*<0.05. (B) The proportion of hCD45⁺ cells in PB of NOG mice was detected in the control and HSA groups at week 16 post-transplantation (n=8). All data represent the means \pm SD by two-tailed unpaired Student's *t*-test. **P*<0.05. (C) NOG mice were sacrificed at 16 weeks post-transplantation for engraftment analysis in BM. The number of recipient mice at different engraftment levels (<2%; 2–10%; 10–30%; 30–50%; >50%) were counted in each group. (D) NOG mice were sacrificed at 16 weeks post-transplantation for SP engraftment analysis. The proportion of hCD45⁺ cells in the SP of recipient mice was detected in each group. (E) Representative flow cytometry profiles of phenotypes at 16 weeks post-transplantation. The engraftment proportions of hCD45⁺ cells were detected in PB, BM, and SP. BM, bone marrow; PB, peripheral blood; SP, spleen; HSA, human serum albumin; NOG, NOD/Shi-scid/IL2R γ null; SD, standard deviation.




Figure 4 HSA maintained multilineage reconstitution capacity in NOG mice. (A) Representative flow cytometry profiles showing lymphoid-lineage hematopoietic reconstitution in BM and SP, including B-lymphoid cells (hCD45⁺CD19⁺), T-lymphoid cells (hCD45⁺CD3⁺), and natural killer cells (NK cells, hCD45⁺CD56⁺). (B) Representative flow cytometry profiles showing myeloid-lineage hematopoietic reconstitution in BM and SP, including myeloid cells (hCD45⁺CD33⁺), megakaryocytes (hCD45⁺CD41⁺), and erythroid cells (hCD45⁺CD235a⁺). BM, bone marrow; SP, spleen; Mk, megakaryocytes; Er, erythroid cells; HSA, human serum albumin; NOG, NOD/Shi-scid/ IL2R γ null.

compounds, coculture systems, and genetic modifications. In our study, we demonstrated that HSA optimized CD34⁺ cell expansion *in vitro* and engraftment *in vivo*. In the future, an efficient HSPC culture strategy could be explored to improve HSPC expansion *in vitro* and optimize engraftment *in vivo*.

Conclusions

We demonstrated that HSA was beneficial to maintaining CD34⁺ cell expansion *in vitro*. What's more, HSA optimized the engraftment of cultured UCB-CD34⁺ cells post-transplantation *in vivo* and retained multilineage potential during culture *in vitro*.

Acknowledgments

Funding: This work was supported by the Youth Fund of Liaocheng People's Hospital (No. LYQN201929).

Footnote

Reporting Checklist: The authors have completed the ARRIVE reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6383/rc>

Data Sharing Statement: Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6383/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-6383/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study was approved by the Ethics Committee of Liaocheng People's Hospital and Clinical School of Shandong First Medical University (No. 2012004), and was conducted in accordance with the Declaration of Helsinki (as revised in 2013). Written informed consent was obtained from all participants included in this study. All animal protocols were approved by the Animal Care and Use Committee of Liaocheng People's Hospital (No. 370726220100172283), in compliance with institutional guidelines for the care and use of animals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Spangrude GJ, Heimfeld S, Weissman IL. Purification and characterization of mouse hematopoietic stem cells. *Science* 1988;241:58-62.
- Uchida N, Tsukamoto A, He D, et al. High doses of purified stem cells cause early hematopoietic recovery in syngeneic and allogeneic hosts. *J Clin Invest* 1998;101:961-6.
- Ogawa M. Differentiation and proliferation of hematopoietic stem cells. *Blood* 1993;81:2844-53.
- Seita J, Weissman IL. Hematopoietic stem cell: self-renewal versus differentiation. *Wiley Interdiscip Rev Syst Biol Med* 2010;2:640-53.
- Civin CI, Strauss LC, Brovall C, et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. *J Immunol* 1984;133:157-65.
- DiGiusto D, Chen S, Combs J, et al. Human fetal bone marrow early progenitors for T, B, and myeloid cells are found exclusively in the population expressing high levels of CD34. *Blood* 1994;84:421-32.
- Huang S, Terstappen LW. Lymphoid and myeloid differentiation of single human CD34⁺, HLA-DR⁺, CD38⁻ hematopoietic stem cells. *Blood* 1994;83:1515-26.
- Miller JS, McCullar V, Punzel M, et al. Single adult human CD34(+)/Lin-/CD38(-) progenitors give rise to natural killer cells, B-lineage cells, dendritic cells, and myeloid cells. *Blood* 1999;93:96-106.
- Williams SF, Lee WJ, Bender JG, et al. Selection and expansion of peripheral blood CD34⁺ cells in autologous stem cell transplantation for breast cancer. *Blood* 1996;87:1687-91.
- Wagner JE, Barker JN, DeFor TE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related

- mortality and survival. *Blood* 2002;100:1611-8.
11. Christopherson KW 2nd, Paganessi LA, Napier S, et al. CD26 inhibition on CD34+ or lineage- human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. *Stem Cells Dev* 2007;16:355-60.
 12. Sauvageau G, Iscove NN, Humphries RK. In vitro and in vivo expansion of hematopoietic stem cells. *Oncogene* 2004;23:7223-32.
 13. Sorrentino BP. Clinical strategies for expansion of haematopoietic stem cells. *Nat Rev Immunol* 2004;4:878-88.
 14. Gilmore GL, DePasquale DK, Lister J, et al. Ex vivo expansion of human umbilical cord blood and peripheral blood CD34(+) hematopoietic stem cells. *Exp Hematol* 2000;28:1297-305.
 15. Xie X, Yao H, Han X, et al. Therapeutic use of red blood cells and platelets derived from human cord blood stem cells. *Stem Cells Transl Med* 2021;10 Suppl 2:S48-53.
 16. Soboleva S, Åkerstrand H, Miharada K. Transcriptomic analysis of functional diversity of human umbilical cord blood hematopoietic stem/progenitor cells in erythroid differentiation. *Int J Hematol* 2022;115:481-8.
 17. Jaroscak J, Goltry K, Smith A, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: results of a phase 1 trial using the AastromReplicell System. *Blood* 2003;101:5061-7.
 18. Boitano AE, Wang J, Romeo R, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. *Science* 2010;329:1345-8.
 19. Li X, Ma X, Chen Y, et al. Coinhibition of activated p38 MAPK α and mTORC1 potentiates stemness maintenance of HSCs from SR1-expanded human cord blood CD34+ cells via inhibition of senescence. *Stem Cells Transl Med* 2020;9:1604-16.
 20. Fares I, Chagraoui J, Gareau Y, et al. Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. *Science* 2014;345:1509-12.
 21. Cszaszar E, Kirouac DC, Yu M, et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. *Cell Stem Cell* 2012;10:218-29.
 22. Duchez P, Chevalyere J, Brunet de la Grange P, et al. Cryopreservation of hematopoietic stem and progenitor cells amplified ex vivo from cord blood CD34+ cells. *Transfusion* 2013;53:2012-9.
 23. Shahzad M, Siddiqui RS, Anwar I, et al. Outcomes with CD34-Selected Stem Cell Boost for Poor Graft Function after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis. *Transplant Cell Ther* 2021;27:877.e1-8.
 24. Tajer P, Pike-Overzet K, Arias S, et al. Ex Vivo Expansion of Hematopoietic Stem Cells for Therapeutic Purposes: Lessons from Development and the Niche. *Cells* 2019;8:169.
 25. Li Y, He M, Zhang W, et al. Antioxidant Small Molecule Compound Chrysin Promotes the Self-Renewal of Hematopoietic Stem Cells. *Front Pharmacol* 2020;11:399.
 26. Goyama S, Wunderlich M, Mulloy JC. Xenograft models for normal and malignant stem cells. *Blood* 2015;125:2630-40.
 27. Yildirim S, Boehmler AM, Kanz L, et al. Expansion of cord blood CD34+ hematopoietic progenitor cells in coculture with autologous umbilical vein endothelial cells (HUVEC) is superior to cytokine-supplemented liquid culture. *Bone Marrow Transplant* 2005;36:71-9.
 28. da Silva CL, Gonçalves R, Crapnell KB, et al. A human stromal-based serum-free culture system supports the ex vivo expansion/maintenance of bone marrow and cord blood hematopoietic stem/progenitor cells. *Exp Hematol* 2005;33:828-35.
 29. Xie CG, Wang JF, Xiang Y, et al. Cocultivation of umbilical cord blood CD34+ cells with retro-transduced hMSCs leads to effective amplification of long-term culture-initiating cells. *World J Gastroenterol* 2006;12:393-402.
 30. Oswald J, Steudel C, Salchert K, et al. Gene-expression profiling of CD34+ hematopoietic cells expanded in a collagen I matrix. *Stem Cells* 2006;24:494-500.
 31. Wilkinson AC, Ishida R, Kikuchi M, et al. Long-term ex vivo haematopoietic-stem-cell expansion allows nonconditioned transplantation. *Nature* 2019;571:117-21.
 32. Moghadasi MH, Hajifathali A, Azad M, et al. Expansion of cord blood stem cells in fibronectin-coated microfluidic bioreactor. *Hematol Transfus Cell Ther* 2022;44:504-11.
 33. Nii T, Konno K, Matsumoto M, et al. The Bioactive Peptide SL-13R Expands Human Umbilical Cord Blood Hematopoietic Stem and Progenitor Cells In vitro. *Molecules* 2021;26:1995.
 34. Sun Q, Zhou Y, Zhu X, et al. Optimizing BIO feeding strategy promotes ex vivo expansion of human

- hematopoietic stem and progenitor cells. *J Biosci Bioeng* 2021;131:190-7.
35. He M, Xu H, Liu G, et al. Levistilide A Promotes

Expansion of Human Umbilical Cord Blood Hematopoietic Stem Cells by Enhancing Antioxidant Activity. *Front Pharmacol* 2022;13:806837.

Cite this article as: Hua J, Jiao T, Qiao Y, Zhang S, Xiao T, Zhang Y, Yan J. Human serum albumin promotes self-renewal and expansion of umbilical cord blood CD34+ hematopoietic stem/progenitor cells. *Ann Transl Med* 2023;11(2):62. doi: 10.21037/atm-22-6383




Figure S1 HSA retained common cell surface markers in CD34⁺HSPCs culture *in vitro*. (A) The proportion of CD38, CD49f, and CD90 in CD34⁺ cell with or without 8 days *in vitro* culture (n=7). All data represent the means \pm SD by two-tailed unpaired Student's *t*-test. (B) Colonies derived from HSA-treated cells following an additional 14 days in MethoCult H4434 Optimum culture (n=7). (C) Representative morphological images of BFU-E colonies derived from cultured UCB-CD34⁺ cells treated with or without HSA. Scale bar, 200 μ m. *, P<0.05. BFU-E, burst-forming unit-erythroid; CFU-E, colony-forming unit-erythrocyte; CFU-GEMM, colony-forming unit-granulocyte/erythrocyte/macrophage/megakaryocyte; CFU-G, colony-forming unit-granulocyte; CFU-M, colony-forming unit-macrophage; HSA, human serum albumin.




Figure S2 HSA sustained multilineage reconstitution in NOG mice. (A) The percentage of lymphoid-lineage hematopoietic reconstitution in BM and SP were detected at week 16 post-transplantation. The proportions of B-lymphoid cells (hCD45⁺CD19⁺), T-lymphoid cells (hCD45⁺CD3⁺), and natural killer cells (NK cells, hCD45⁺CD56⁺) were compared between the control and HSA groups (n=8). All data represent the means \pm SD by two-tailed unpaired Student's *t*-test. (B) The percentage of myeloid-lineage hematopoietic reconstitution in BM and SP were detected at week 16 post-transplantation. The proportions of myeloid cells (hCD45⁺CD33⁺), megakaryocytes (hCD45⁺CD41⁺), and erythroid cells (hCD45⁺CD235a⁺) were compared between the control and HSA groups (n=8). All data represent the means \pm SD by two-tailed unpaired Student's *t*-test. BM, bone marrow; SP, spleen; HSA, human serum albumin.